Towercrest Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Towercrest Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-5,050	Closed	-$479K	–	110
2024 Q1	$479K	Hold	5,050	–	–	0.08%	76
2023 Q4	$451K	Hold	5,050	–	–	0.08%	73
2023 Q3	$369K	Buy	+5,050	New	+$403K	0.07%	79
2019 Q1	–	Sell	-8,750	Closed	-$628K	–	75
2018 Q4	$628K	Buy	+8,750	New	+$705K	0.2%	48

Other funds holding XBI

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Towercrest Capital Management's XBI Position: Q2 2024 in Review

Towercrest Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2024, closing a stake of 5,050 shares — an estimated $479K sold.

Towercrest Capital Management first reported a position in XBI in Q4 2018 and held it in 4 quarters. The position peaked at $628K in Q4 2018. 761 funds tracked by Wall St. Rank hold XBI as of Q2 2024.

Towercrest Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2024 after selling out during the quarter.
Towercrest Capital Management sold 5,050 State Street SPDR S&P Biotech ETF shares in Q2 2024, an estimated $479K.
Towercrest Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2018 and held it in 4 quarters.
Towercrest Capital Management's State Street SPDR S&P Biotech ETF position peaked at $628K in Q4 2018.
761 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2024.

Based on Towercrest Capital Management's 13F filing for Q2 2024, filed 6 Aug 2024.